文献速递浆细胞疾病造血干细胞移植与细胞治疗

口服美法仑作为多发性骨髓瘤自体移植预处理方案的疗效与安全性

[Efficacy and safety of oral melphalan as conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

这项回顾性队列研究纳入48例接受auto-HSCT的多发性骨髓瘤患者,比较口服美法仑(12例)与静脉美法仑(36例)的植入时间、疗效、不良反应及药代动力学。口服组中性粒细胞和血小板植入较慢、粒细胞最低值较高,但胃肠道不良反应显著减少,移植后疗效及生存无显著差异;口服组美法仑暴露量为静脉组的82.2%,生物利用度良好。

要点

  • 口服美法仑组中性粒细胞和血小板植入时间较静脉组延长,但粒细胞最低值较高。
  • 口服组恶心、呕吐、腹泻发生率显著低于静脉组,口腔黏膜炎及肝肾损害无差异。
  • 两组移植后疗效及无进展生存、总生存均无显著差异,口服美法仑生物利用度良好。

核心结论

  • 口服美法仑作为多发性骨髓瘤患者auto-HSCT预处理方案生物利用度良好,不良反应发生率低,临床疗效良好。

研究设计与样本

  • 回顾性队列研究,纳入2022年7月至2023年10月在上海交通大学医学院附属瑞金医院接受auto-HSCT的多发性骨髓瘤患者48例,口服组12例、静脉组36例。
  • 根据美法仑给药途径分组,观察植入时间、疗效、长期预后及不良事件,并用质谱技术检测6例患者(口服组3例、静脉组3例)的美法仑血药浓度。

主要发现

  • 口服组中性粒细胞降至最低值时间中位9.0(7.0~13.0)d、植入时间中位12.0(10.0~14.0)d,均长于静脉组的7.0(5.0~12.0)d和11.0(9.0~12.0)d,P<0.001。
  • 口服组血小板降至最低值时间中位10.0(9.0~15.0)d、植入时间中位14.5(11.0~17.0)d,均长于静脉组的9.0(6.0~13.0)d和12.0(9.0~19.0)d,P分别为0.004和0.002。
  • 口服组中性粒细胞最低值中位0.11(0.01~0.24)×10^9/L,高于静脉组的0.02(0.01~0.15)×10^9/L,P<0.001;两组血小板最低值差异无统计学意义(P>0.05)。
  • 口服组恶心发生率50.0%对100.0%(P<0.001)、呕吐8.3%对69.5%(P=0.001)、腹泻50.0%对83.3%(P=0.030),均低于静脉组。
  • 中位随访37.9(31.0~49.4)个月,口服组和静脉组中位无进展生存期分别为未达到和35.9个月(95%CI:28.3个月~未达到),差异无统计学意义(P>0.05),两组中位总生存期均未达到。

关键数值与推荐

  • 两组移植后获得非常好的部分缓解及以上比例及完全缓解率差异均无统计学意义(P>0.05)。
  • 口服组与静脉组粒细胞缺乏(<0.5×10^9/L)和血小板降低(<20×10^9/L)中位持续时间差异均无统计学意义(P值均>0.05)。
  • 两组口腔黏膜炎、肝肾功能损害发生率差异均无统计学意义(P值均>0.05)。
  • 两组美法仑达到血药峰浓度时间均在化疗开始后30 min,口服组平均浓度-时间曲线下面积为静脉组的82.2%,生物利用度差异无显著统计学意义。

临床怎么用

  • 口服美法仑可作为多发性骨髓瘤auto-HSCT预处理方案,但需预期中性粒细胞和血小板植入时间较静脉组延长。
  • 口服美法仑胃肠道不良反应较少,可考虑用于静脉美法仑胃肠道耐受性差的患者。
  • 口服美法仑粒细胞最低值较高,但粒细胞缺乏持续时间与静脉组相当,临床监测策略可参考静脉组。

局限性

  • 本研究为单中心回顾性队列研究,样本量较小(共48例,口服组仅12例)。
  • 药代动力学评价仅纳入6例患者(口服组3例、静脉组3例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the safety and efficacy of oral melphalan as a conditioning regimen for patients with multiple myeloma (MM) who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) . Methods: This retrospective cohort study collected clinical data of patients with MM who underwent auto-HSCT at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from July 2022 to October 2023. Patients were divided into oral and intravenous groups according to the administration route of melphalan. Engraftment time (ET), overall responses, long-term outcomes, and melphalan-associated toxicities were assessed. The pharmacokinetics of melphalan were detected using a mass spectrometer. Results: This study included 48 patients with MM who met the inclusion and exclusion criteria. Of these patients, 12 received tablet melphalan and 36 had the injection formulation. Upon engraft infusion, time to the lowest level (TTLL) and ET of neutrophils in the oral group were significantly longer than those in the injection group[TTLL: median, 9.0 (7.0-13.0) d vs 7.0 (5.0-12.0) d, P<0.001; ET: median, 12.0 (10.0-14.0) d vs 11.0 (9.0-12.0) d, P<0.001]. Such a lag also happened to the TTLL and ET of platelets in the oral group compared with the injection group[TTLL: median 10.0 (9.0-15.0) d vs 9.0 (6.0-13.0) d, P=0.004; ET: median, 14.5 (11.0-17.0) d vs 12.0 (9.0-19.0) d, P=0.002]. The lowest level of neutrophils in the oral group was higher than that in the injection group (0.11×10(9)/L vs 0.02×10(9)/L, P<0.001), whereas the lowest level of platelets in both groups had no statistical difference (P>0.05). The median duration of neutropenia (<0.5×10(9)/L) was comparable between the two groups. Regarding non-hematological side effects, patients who took melphalan orally had a remarkably lower frequency of gastrointestinal toxicities as opposed to those given intravenously (nausea: 50.0% vs 100.0%, P<0.001; vomiting: 8.3% vs 69.5%, P=0.001; diarrhea: 50.0% vs 83.3%, P=0.030). The incidence of oral mucositis and liver or kidney impairments did not differ between the two groups. Post-auto-HSCT efficacy evaluation demonstrated no differences in the percentages of patients obtaining a very good partial response and better outcomes, as well as in the improvement rate to complete remission. With a median follow-up time of 37.9 (31.0 - 49.4) months, the median progression-free survival (PFS) of the oral and injection groups was not reached and 35.9 months (95% CI: 28.3 months-not reached), respectively. Median overall survival (OS) was not reached for either. Neither PFS nor OS reached statistical significance between the two groups. To examine the drug bioavailability, melphalan pharmacokinetics were tested in 6 patients, comprising 3 from the oral group and 3 from the injection group. The result demonstrated that both formulations reached their peak levels in 30 min. Although the oral melphalan exposure on average was 82.2% of the injection dosage form, there was no significant difference in bioavailability. Conclusions: Oral melphalan, as a conditioning regimen for auto-HSCT in paients with MM, demonstrated favorable bioavailability, a low incidence of adverse reactions, and good clinical efficacy. 目的: 探索口服美法仑作为多发性骨髓瘤(MM)自体造血干细胞移植(auto-HSCT)预处理方案的疗效和安全性。 方法: 本项回顾性队列研究收集2022年7月至2023年10月在上海交通大学医学院附属瑞金医院进行auto-HSCT的MM患者的临床资料。根据美法仑的应用方式分为口服组和静脉组,观察两组患者移植后粒细胞、血小板植入时间(ET),移植后疗效,长期预后及治疗期间出现的不良事件。采用质谱技术检测患者美法仑血药浓度。 结果: 共纳入48例新诊断MM患者,口服组12例,静脉组36例。造血干细胞回输后,口服组中位ANC降至最低值时间(TTLL)和ET均较静脉组延长[TTLL:9.0(7.0~13.0)d对7.0(5.0~12.0)d,P<0.001;ET:12.0(10.0~14.0)d对11.0(9.0~12.0)d,P<0.001];血小板表现出相似的差异[TTLL:10.0(9.0~15.0)d对9.0(6.0~13.0)d,P=0.004;ET:14.5(11.0~17.0)d对12.0(9.0~19.0)d,P=0.002]。口服组中位ANC最低值较静脉组高[(0.11(0.01~0.24)×10(9)/L对0.02(0.01~0.15)×10(9)/L,P<0.001],两组中位PLT最低值的差异无统计学意义(P>0.05)。口服组与静脉组粒细胞缺乏(<0.5×10(9)/L)和PLT降低(<20×10(9)/L)中位持续时间的差异均无统计学意义(P值均>0.05)。非血液学不良反应方面,口服组胃肠道不良反应的发生率较静脉组显著降低(恶心:50.0%对100.0%,P<0.001;呕吐:8.3%对69.5%,P=0.001;腹泻:50.0%对83.3%,P=0.030)。两组口腔黏膜炎、肝肾功能损害的发生率差异均无统计学意义(P值均>0.05)。两组移植后疗效获得非常好的部分缓解以上比例及完全缓解率的差异也均无统计学意义(P值均>0.05)。中位随访时间37.9(31.0~49.4)个月,口服组和静脉组中位无进展生存期分别为未达到和35.9个月(95%CI:28.3个月~未达到),差异无统计学意义(P>0.05),两组的中位总生存期均未达到。6例患者(口服组3例,静脉组3例)接受了美法仑药代动力学评价,两组达到血药峰浓度的时间均在化疗开始后30 min,口服组平均浓度-时间曲线下面积是静脉组的82.2%。 结论: 口服美法仑作为MM患者auto-HSCT的预处理方案生物利用度良好,不良反应发生率低,临床疗效良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang J, Gong L, Pan MM, et al. [Efficacy and safety of oral melphalan as conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706175. doi:10.3760/cma.j.cn121090-20260126-00060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。